Of clinical relevance, elevated OTUD4 expression is associated with poorer outcomes in breast cancer and facilitates TGF-β signaling—a pathway critically involved in epithelial–mesenchymal transition (EMT) and metastatic dissemination [39,42]. Here, OTUD4 is linked to breast cancer.